EyePoint's DURAVYU misses primary endpoint in wet AMD trial

August 17, 2026 7:01 AM

EyePoint, Inc. (NASDAQ: EYPT) announced topline results from LUGANO, the first of two pivotal Phase 3 clinical trials evaluating DURAVYU ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found